Skip to main content

Volume 11 Supplement 1

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review


Edited by Josef Smolen

Publication of this supplement has been sponsored by F. Hoffmann-La Roche.

  1. Conventional disease-modifying antirheumatic drugs such as methotrexate are the mainstay of treatment for rheumatoid arthritis. More recently, biologic agents such as etanercept, infliximab and adalimumab, whi...

    Authors: Andrea Rubbert-Roth and Axel Finckh
    Citation: Arthritis Research & Therapy 2009 11(Suppl 1):S1

Annual Journal Metrics